Group 1 - The company announced a cash dividend of 0.25 yuan per share (including tax) to all shareholders based on the total share capital after deducting shares held in the repurchase account [1][3] - The company will stop the conversion of its convertible bonds ("华海转债") from July 1, 2025, until the record date for the dividend distribution, with resumption of conversion on the first trading day after the record date [1][3] - The company will adjust the conversion price of the convertible bonds according to the terms outlined in the bond issuance prospectus after the implementation of the profit distribution plan [3] Group 2 - The company held its annual general meeting on May 23, 2025, where the profit distribution plan was approved [1][2] - The company will publish the implementation announcement of the profit distribution and the adjustment of the convertible bond conversion price on July 2, 2025 [3] - Shareholders wishing to enjoy the dividend distribution must convert their bonds by June 30, 2025 [3]

证券代码：600521 证券简称：华海药业 公告编号：临 2025-075 号 转债代码：110076 转债简称：华海转债 浙江华海药业股份有限公司 一、2024 年度权益分派方案的基本情况 浙江华海药业股份有限公司（以下简称"公司"）于 2025 年 5 月 23 日召开 2024 年年度股东大会，会议审议通过了《公司 2024 年度利润分配方案》，公司以实施 权益分派股权登记日登记的总股本扣除公司回购专用证券账户股份数后的股本为 基数，向全体股东每股派发现金红利 0.25 元（含税）。公司通过回购专用证券账 户所持有本公司股份不参与本次利润分配。如在实施权益分派股权登记日期前， 因可转债转股、回购股份注销等致使公司总股本发生变动的，公司将维持每股分 配金额不变，相应调整分配总额。 具体内容详见公司分别于 2025 年 4 月 30 日、2025 年 5 月 24 日刊登在中国证 券报、上海证券报、证券时报、证券日报及上海证券交易所网站（www.sse.com.cn） 关于实施 2024 年度权益分派时"华海转债"停止转股 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或 ...

Group 1 - The core viewpoint of the report is the management of the convertible bonds issued by Zhejiang Huahai Pharmaceutical Co., Ltd., including the bond's issuance details, credit ratings, and the use of raised funds [1][2][3][4][5][6][7][8][9] Group 2 - The total amount of the convertible bonds issued is 1,842.60 million yuan, with a term of 6 years and an interest rate that varies from 0.30% in the first year to 1.00% in the third year [1][2] - The funds raised will be allocated to various projects, including 692.60 million yuan for the production of 20 tons of Perindopril and 50 tons of Ramipril, and 600 million yuan for a pharmaceutical and R&D center project [1][6] - The company has maintained a credit rating of AA for both the issuer and the bonds, with a stable outlook [1][2][3] Group 3 - The company reported a 14.91% increase in total revenue for 2024, amounting to 954,742.54 million yuan compared to 830,871.98 million yuan in 2023 [5] - The net profit for 2024 reached 110,746.31 million yuan, reflecting a 35.51% increase from the previous year [5] - The company’s total assets and liabilities remained stable, with total liabilities at 112.41 billion yuan as of December 31, 2024 [7][9] Group 4 - The company has established a mechanism for the management of raised funds, ensuring compliance with the intended use as outlined in the bond issuance documents [6][7] - The company has successfully completed the projects funded by the raised capital, including the production of raw materials and the establishment of a pharmaceutical park [6][7] - The company has reported no significant adverse changes in its operating environment or business continuity [4][6]

Core Viewpoint - The report provides a comprehensive analysis of the financial status, operational performance, and market conditions of the company, focusing on its recent developments and future outlook in the pharmaceutical industry. Financial Data and Indicators - The company's cash and cash equivalents are projected to increase from 2.93 billion yuan in 2022 to 4.94 billion yuan by the end of 2024, indicating a growth trend [3] - The total assets are expected to rise from 23.00 billion yuan in 2022 to 34.89 billion yuan by the end of 2024, reflecting a strong asset base [3] - The net profit is forecasted to grow from 2.70 billion yuan in 2022 to 5.12 billion yuan in 2024, showcasing significant profitability [4] - The operating cash flow is anticipated to increase from 1.92 billion yuan in 2022 to 6.13 billion yuan by 2024, indicating improved cash generation capabilities [3] Business Operations - The company focuses on the research, production, and sales of pharmaceutical products, with a core revenue source from drug formulations, accounting for over 80% of its core business income [8][9] - The main products include pain relief and digestive system medications, with significant sales growth in OTC channels and online markets [10][11] - The company has expanded its production capacity, with a new high-end formulation research and development park completed in March 2023, enhancing its production capabilities for key products [12] Market Conditions - The pharmaceutical industry is facing challenges from price control policies and increased competition, leading to a slight decline in profit margins [7][8] - Despite short-term pressures, the long-term outlook for the industry remains positive due to factors such as aging population and rising health awareness, which are expected to drive demand [7][8] - The company has successfully participated in multiple provincial-level centralized procurement projects, which has increased sales volume but also led to a decrease in sales prices due to competitive bidding [14] Future Outlook - The company plans to invest in additional production lines for raw materials and pharmaceutical excipients, with ongoing projects expected to enhance production capacity significantly by 2026 [12][13] - The anticipated increase in production capacity and ongoing market expansion efforts are expected to support revenue growth in the coming years, despite current market challenges [10][11]

浙商证券股份有限公司 关于 浙江华海药业股份有限公司 公开发行可转换公司债券 受托管理事务报告 （2024 年度） | 债券代码 | 债券简称 | | --- | --- | | 110076 | 华海转债 | 债券受托管理人 （注册地址：浙江省杭州市五星路 201 号） 二〇二五年六月 1 | 重要声明 2 | | --- | | 目录 3 | | 第一章 本次债券情况 4 | | 第二章 受托管理人履行职责情况 6 | | 第三章 发行人的经营与财务状况 8 | | 第四章 发行人募集资金使用及专项账户运作情况与核查情况 11 | | 第五章 内外部增信机制、偿债保障措施的有效性分析 17 | | 第六章 债券本息偿付情况以及发行人偿债保障措施的执行情况 18 | | 第七章 发行人在募集说明书中约定的其他义务的执行情况 19 | | 第八章 债券持有人会议的召开情况 20 | | 第九章 发行人偿债意愿和能力分析 21 | | 第十章 可能影响发行人偿债能力的重大事项及受托管理人采取的应对措施 23 | | 第十一章 其他事项 24 | 第一章 本次债券情况 一、可转换公司债券基本情况 重要声明 浙商证 ...

医药生物行业资金流出榜 （原标题：14.41亿元主力资金今日抢筹医药生物板块） 沪指6月23日上涨0.65%，申万所属行业中，今日上涨的有28个，涨幅居前的行业为计算机、国防军工，涨幅分别为2.25%、1.97%。医药生物行业 今日上涨0.89%。跌幅居前的行业为食品饮料、家用电器、钢铁，跌幅分别为0.80%、0.43%、0.11%。 医药生物行业今日上涨0.89%，全天主力资金净流入14.41亿元，该行业所属的个股共475只，今日上涨的有400只，涨停的有6只；下跌的有65只， 跌停的有1只。以资金流向数据进行统计，该行业资金净流入的个股有247只，其中，净流入资金超亿元的有5只，净流入资金居首的是永安药业， 今日净流入资金2.35亿元，紧随其后的是塞力医疗、华海药业，净流入资金分别为1.65亿元、1.25亿元。医药生物行业资金净流出个股中，资金净 流出超3000万元的有9只，净流出资金居前的有众生药业、创新医疗、新诺威，净流出资金分别为1.42亿元、6423.29万元、5901.06万元。（数据 宝） 医药生物行业资金流入榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量 ...

Group 1 - The China Securities 500 Quality Growth Index (930939) experienced a decline of 0.49% as of June 23, 2025, with mixed performance among constituent stocks [1] - Leading gainers included Huahai Pharmaceutical (600521) up by 4.11%, Tongfu Microelectronics (002156) up by 3.48%, and CNOOC Development (600968) up by 2.15% [1] - The 500 Quality Growth ETF (560500) fell by 0.63%, with a latest price of 0.95 yuan and a trading volume of 1.5987 million yuan, while it saw a net inflow of 4.7992 million yuan over the past three days [1] Group 2 - Guotai Junan Securities noted that after short-term risk release, the core contradiction in the Chinese stock market remains internal rather than external, with a more optimistic outlook than consensus [2] - The firm highlighted that new technologies and consumer opportunities are emerging, stabilizing economic expectations, and that the reduction in risk-free rates has lowered the opportunity cost of investing in stocks [2] - The 500 Quality Growth ETF closely tracks the China Securities 500 Quality Growth Index, which is characterized by small and mid-cap value growth styles, with better profitability and lower valuations post-adjustment [2] Group 3 - As of May 30, 2025, the top ten weighted stocks in the China Securities 500 Quality Growth Index included Chifeng Jilong Gold Mining (600988), Ninebot (689009), and Shenghong Technology (300476), collectively accounting for 23.79% of the index [3] Group 4 - The performance of the top ten weighted stocks showed varied results, with Chifeng Jilong Gold Mining (600988) down by 0.22% and Ninebot (689009) down by 2.39%, while Crystal Optoelectronics (002273) increased by 1.89% [4]

创新药概念午后回暖 塞力医疗触及涨停 智通财经6月23日电，午后创新药概念震荡反弹，塞力医疗触及涨停，微芯生物涨近15%，热景生物、 神州细胞、华海药业、益方生物、舒泰神、美迪西等跟涨。消息面上，国家药监局出台征求意见稿，提 到"对符合要求的创新药临床试验申请在30个工作日内完成审评审批"，鼓励创新药研发上市。 ...

Index Performance - The CSI A500 Index decreased by 0.89% this week, closing at 4492.54 points on June 20 [5] - The average daily trading volume for the week was 3111.51 billion yuan, with a week-on-week decline of 17.81% [5][6] Component Stocks Performance - The top ten gainers this week included: 1. Yinghe Technology (300457.SZ) with a rise of 25.88% 2. Dongshan Precision (002384.SZ) up by 15.42% 3. Huadian Co. (002463.SZ) increasing by 11.89% 4. Zhongji Xuchuang (300308.SZ) up by 11.46% 5. Xinyi Sheng (300502.SZ) rising by 9.96% 6. Defang Nano (300769.SZ) up by 9.81% 7. Giant Network (002558.SZ) increasing by 8.89% 8. Watson Bio (300142.SZ) up by 8.63% 9. Shenghong Technology (300476.SZ) rising by 8.12% 10. Sanqi Interactive (002555.SZ) up by 6.80% [4] - The top ten losers included: 1. Kailaiying (002821.SZ) down by 9.50% 2. Chenguang Co. (603899.SH) decreasing by 9.74% 3. Nianhai Pharmaceutical (600521.SH) down by 9.76% 4. Baili Tianheng (688506.SH) decreasing by 10.02% 5. Changchun Gaoxin (000661.SZ) down by 10.49% 6. Deyue Co. (605117.SH) decreasing by 11.00% 7. Guolian Co. (603613.SH) down by 11.27% 8. Betta Pharmaceuticals (300558.SZ) decreasing by 13.09% 9. Aofei Entertainment (002292.SZ) down by 13.35% 10. Xinlitai (002294.SZ) decreasing by 14.64% [4] Fund Performance - All 35 CSI A500 funds experienced declines this week, with Tianhong, Xinyi, and Guotai showing declines greater than 1% [6] - The total scale of funds fell below 200 billion yuan, with the top three being Guotai (193.06 billion yuan), GF (168.77 billion yuan), and Southern (161.04 billion yuan) [6]

内容概要：台州市是浙江省下辖的地级市，位于浙江省中部沿海。近年来，台州市围绕打造"5+5+6"台 州特色现代化产业体系，一手抓传统产业、优势产业的巩固和优化，瞄准链主型企业、专精特新"小巨 人"企业等开展靶向招引，提升平台首位产业辨识度；一手抓新兴产业、未来产业的培育和壮大，聚焦 算力、氢能、低空经济、合成生物、机器人、泛半导体等六大未来产业，加快发展新质生产 力。"5+5+6"产业发展不断实现新突破，竞争力持续增强，产业生态日益完善，现代产业基础不断夯 实，助力经济稳步增长。 上市企业：水晶光电（002273）、航天彩虹（002389）、海正药业（600267）、海翔药业（002099）、 九洲药业（603456）、杰克股份（603337）、信质集团（002664）、百达精工（603331）、海正生材 （688203）、夜光明（873527）、华海药业（600521）、浙江永强（002489）、伟星股份（002003）、 伟星新材（002372）、永太科技（002326）、万盛股份（603010）、奥翔药业（603229）、本立科技 （301065）、联盛化学（301212）、浙江正特（001238）、天山 ...